Graft-Versus-Host Disease Pipeline Assessment

The Graft versus Host Disease (GvHD) market is anticipated to experience significant growth due to the market penetration of approved therapies, the expected label expansions, and the rapid adoption of emerging therapies. Additionally, increasing awareness of cellular therapies, regulatory support for research, and innovation are also projected to contribute to the market’s growth.

Major pharmaceutical giants such as CSL Behring [CSL 964 Alpha-1 antitrypsin (AAT)], Medac [obnitix (MC0518)], Equillium/Biocon [itolizumab], OncoImmune/Merck (MSD) [MK-7110 (CD24Fc)], ElsaLys Biotech/Mediolanum Farmaceutici Spa [Leukotac (inolimomab)], Xenikos [T-Guard], Mesoblast/Osiris Therapeutics [RYONCIL (remestemcel-L; prochymal)], Syndax Pharmaceutical [axatilimab (SNDX-6532)], and Regimmune Corporation (RGI-2001), among others, are actively engaged in the development of novel therapies.

DelveInsight’s, “Graft versus host disease (GVHD) Pipeline Insight, 2024,” report provides comprehensive insights about 45+ GvHD companies and 50+ pipeline drugs in Graft versus host disease (GVHD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

The Graft-Versus-Host Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from pre-clinical developmental to marketed phases. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Graft versus host disease Overview

Graft versus host disease (GVHD) is a severe complication that arises when donor immune cells attack the recipient’s body following an allogeneic stem cell or bone marrow transplant. This condition occurs because the donor’s immune cells identify the recipient’s cells as foreign and initiate an immune response against them. GVHD primarily involves T-cells from the donor graft and is categorized into two main types: acute and chronic. Acute GVHD typically develops within the first 100 days post-transplant, presenting symptoms such as skin rashes, jaundice, liver enzyme abnormalities, and diarrhea. Chronic GVHD, on the other hand, emerges after 100 days and can affect multiple organs, leading to symptoms like skin thickening, joint contractures, dry eyes, and lung dysfunction.

The risk of developing GVHD is influenced by several factors, including the degree of HLA matching between donor and recipient, the type of donor, and the recipient’s age. A mismatched HLA significantly increases the risk, as does the use of unrelated or haploidentical donors and cord blood transplants compared to matched sibling donors. Older recipients are also more susceptible to GVHD, and the intensity of the conditioning regimen (pre-transplant chemotherapy or radiation) plays a critical role in the disease’s development. Diagnosis is based on clinical presentation, biopsy of affected tissues, and the exclusion of other potential causes of symptoms.

Preventive measures are essential in managing GVHD, with prophylactic immunosuppressive therapies such as cyclosporine, tacrolimus, methotrexate, and mycophenolate mofetil commonly used. Treatment of acute GVHD generally involves high-dose corticosteroids, with additional immunosuppressive agents like ruxolitinib and antithymocyte globulin (ATG) used for steroid-refractory cases. Chronic GVHD treatment also includes corticosteroids and calcineurin inhibitors, with newer therapies such as ibrutinib and ruxolitinib for refractory cases. Despite these treatments, GVHD can lead to significant morbidity and mortality due to direct organ damage and increased infection risk from prolonged immunosuppression.

The prognosis for GVHD varies widely; acute GVHD presents an immediate risk of severe outcomes, while chronic GVHD can cause long-term health issues. Effective prevention and treatment strategies are essential to improving patient outcomes and quality of life. Complications of GVHD include chronic infections, secondary cancers, and debilitating organ dysfunction, underscoring the importance of ongoing management and monitoring.

Research is continuously advancing to better understand the mechanisms underlying GVHD and to develop more targeted therapies. Innovations in immunotherapy and personalized medicine approaches hold promise for reducing the incidence and severity of GVHD. These advancements are crucial for enhancing the success rates of transplants and improving the overall prognosis for patients affected by this challenging condition.

Graft-Versus-Host Disease (GVHD) Pipeline Analysis

The report provides insights into: 

• The report provides detailed insights into the emerging therapies for the treatment of Graft-Versus-Host Disease and the aggregate therapies developed by major pharma companies.

• It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

• It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Graft-Versus-Host Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) 

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Route of Administration

GVHD pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Graft versus host disease products has been categorized under various ROAs, such as

• Oral

• Intravenous

• Subcutaneous 

Molecule Type

Graft versus host disease Products have been categorized under various Molecule types, such as

• Small molecule

• Cell Therapy

• Peptides

• Polymer

• Small molecule

• Gene therapy

Learn How the Ongoing Clinical & Commercial Activities will Affect the Graft-Versus-Host Disease Therapeutic Segment @ https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-pipeline-insight

Graft-Versus-Host Disease  (GVHD) Therapeutics Landscape

Several major pharmaceutical and biotechnology companies are actively engaged in the Graft versus Host Disease (GVHD) therapeutics market. Currently, ElsaLys Biotech is at the forefront of this segment, with its drug candidates in the most advanced stages of clinical development.

Leading Companies in the Graft-Versus-Host Disease (GVHD) Therapeutics Market Include:

AltruBio, Amgen, ASC Therapeutics, AstraZeneca, Biogen, Bristol-Myers Squibb, Chia Tai Tianqing Pharmaceutical Group, CSL Behring, CTI BioPharma, ElsaLys Biotech (Mediolanum Farmaceutici Spa), Equillium, GlaxoSmithKline, Glia, Incyte Corporation, Jazz Pharmaceuticals, JCR therapeutics, Kadmon Corporation, MaaT Pharma, Medac, Medsenic, Mesoblas, Millennium Pharmaceuticals/Takeda Oncology, Novartis, OncoImmune/Merck (MSD), Osiris Therapeutics, Pfizer, Plexxikon, Prevention Bio, REGiMMUNE, Regimmune Corporation, Roche-Genentech, SCM Lifescience, Syndax Pharmaceuticals, Synthetic Biologics, Takeda, VectivBio, Xenikos, Xenothera, and others.

Graft-Versus-Host Disease (GVHD) Emerging and Marketed Drugs Covered in the Report Include:

• AbGn-168H (Neihulizumab): AltruBio

• Arscimed (arsenic trioxide): Medsenic

• ASC930: ASC Therapeutics

• Calquence (Acalabrutinib): AstraZeneca

• CSL 964 Alpha-1 antitrypsin (AAT): CSL Behring

• Efavaleukin Alfa (AMG 592): Amgen

• EQ001 (Itolizumab; Bmab600): Equillium/Biocon

• Itacitinib: Incyte Corporation

• Jakafi (Ruxolitinib): Incyte Corporation

• KD025 (Belumosudil): Kadmon Corporation

• Leukotac (Inolimomab): ElsaLys Biotech (Mediolanum Farmaceutici Spa)

• MaaT013: MaaT Pharma

• MK-7110 (CD24Fc): OncoImmune/Merck (MSD)

• Obnitix (MC0518): Medac

• Pacritinib (Epjevy; ONX-0803): CTI BioPharma

• RGI-2001: Regimmune Corporation

• SNDX-6532 (Axatilimab; GvHD B6352): Syndax Pharmaceutical

• T-Guard: Xenikos

• Temcell (Ryoncil; Remestemcel-L; Prochymal): JCR therapeutics/ Mesoblast/ Osiris Therapeutics

• Teplizumab: Prevention Bio

• Imbruvica (Ibrutinib): Pharmacyclics (Acquired by Abbvie)/ Janssen

• Jakafi (Ruxolitinib): Incyte Corporation

• Ornecia (abatacept): Bristol Mayers Squibb

• Rezurock (Belumosudil): Kadmon Corporation (Subsidiary of Sanofi)

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @ https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-pipeline-insight

Table of Contents

1. Report Introduction

2. Executive Summary

3. Graft-Versus-Host Disease Current Treatment Patterns

4. Graft-Versus-Host Disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Graft-Versus-Host Disease Late-Stage Products (Phase-III)

7. Graft-Versus-Host Disease Mid-Stage Products (Phase-II)

8. Graft-Versus-Host Disease Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Graft-Versus-Host Disease Discontinued Products

13. Graft-Versus-Host Disease Product Profiles

14. Key Companies in the Graft-Versus-Host Disease Market

15. Key Products in the Graft-Versus-Host Disease Therapeutics Segment

16. Dormant and Discontinued Products

17. Graft-Versus-Host Disease Unmet Needs

18. Graft-Versus-Host Disease Future Perspectives

19. Graft-Versus-Host Disease Analyst Review  

20. Appendix

21. Report Methodology

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/